Skip to content
HowShorted

Novavax, Inc. short interest in 2025

In 2025, Novavax, Inc.'s disclosed short interest ran from 23.77% of shares outstanding on 15 Jan 2025 to 33.68% on 31 Dec 2025, a change of +9.91 percentage points. The year's high was 33.68% on 31 Dec 2025 and its low 21.81% on 31 Jan 2025, averaging 26.96% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.09 days on 15 Dec 2025. Full history: Novavax, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Novavax, Inc. in 2025

2025 in figures

Start of year
23.77% (15 Jan 2025)
End of year
33.68% (31 Dec 2025)
Change
+9.91 pp
High
33.68% (31 Dec 2025)
Low
21.81% (31 Jan 2025)
Average
26.96%
Highest days to cover
17.09 (15 Dec 2025)
SEC filings marked
9

Every report in 2025

Novavax, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202523.77%6.27results (8-K)
31 Jan 202521.81%8.76
14 Feb 202522.13%12.70
28 Feb 202524.39%6.3910-K filed, results (8-K)
14 Mar 202523.35%9.50
31 Mar 202522.93%11.80
15 Apr 202525.51%5.03
30 Apr 202526.14%6.40
15 May 202528.69%4.3110-Q filed, results (8-K)
30 May 202527.60%2.65
13 Jun 202527.46%7.57
30 Jun 202528.74%9.06
15 Jul 202526.60%9.82
31 Jul 202526.05%7.70
15 Aug 202523.46%4.0610-Q filed, results (8-K)
29 Aug 202527.01%4.90
15 Sep 202527.54%9.14
30 Sep 202526.75%10.93
15 Oct 202528.22%9.01
31 Oct 202529.74%12.92
14 Nov 202531.19%10.4710-Q filed, results (8-K)
28 Nov 202531.91%13.39
15 Dec 202532.36%17.09
31 Dec 202533.68%17.00

See also: Novavax, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.